中西医结合心血管病电子杂志
中西醫結閤心血管病電子雜誌
중서의결합심혈관병전자잡지
Cardiovascular Disease Journal of Integrated Traditional Chinese and Western Medicine (Electronic)
2014年
6期
6-6
,共1页
李钢%郭菁%梁韶春%侯国娜%梁丽丽%李俊%李腾娇
李鋼%郭菁%樑韶春%侯國娜%樑麗麗%李俊%李騰嬌
리강%곽정%량소춘%후국나%량려려%리준%리등교
慢性心房颤动%乙胺碘呋酮%奎尼丁%索他洛尔%莫雷西嗪%预后%Meta分析
慢性心房顫動%乙胺碘呋酮%奎尼丁%索他洛爾%莫雷西嗪%預後%Meta分析
만성심방전동%을알전부동%규니정%색타락이%막뢰서진%예후%Meta분석
chronic atrial fibrillation%amiodarone%quinidine%sotalol%moricizine%prognosis%Meta analysis
目的：比较近年来慢性心房纤颤奎尼丁、乙胺碘呋酮、莫雷西嗪、索他洛尔疗效。方法在中文CNKI数据库中检索文献，纳入心房纤颤四种药物随机对照试验，采用Revman5．0软件进行Meta分析。结果以奎尼丁、乙胺碘呋酮疗效较好。有效率高于索他洛尔和莫雷西嗪，差异有统计学意义（P＜0．05）。结论 Meta分析表明、在60岁之前患者，除颤成功与否与预后有密切关系，而60岁以上人群，除颤是否成功与预后关系不大目前治疗房颤最有效、而且副作用最小的药物仍推荐乙胺碘呋酮。
目的：比較近年來慢性心房纖顫奎尼丁、乙胺碘呋酮、莫雷西嗪、索他洛爾療效。方法在中文CNKI數據庫中檢索文獻，納入心房纖顫四種藥物隨機對照試驗，採用Revman5．0軟件進行Meta分析。結果以奎尼丁、乙胺碘呋酮療效較好。有效率高于索他洛爾和莫雷西嗪，差異有統計學意義（P＜0．05）。結論 Meta分析錶明、在60歲之前患者，除顫成功與否與預後有密切關繫，而60歲以上人群，除顫是否成功與預後關繫不大目前治療房顫最有效、而且副作用最小的藥物仍推薦乙胺碘呋酮。
목적：비교근년래만성심방섬전규니정、을알전부동、막뢰서진、색타락이료효。방법재중문CNKI수거고중검색문헌，납입심방섬전사충약물수궤대조시험，채용Revman5．0연건진행Meta분석。결과이규니정、을알전부동료효교호。유효솔고우색타락이화막뢰서진，차이유통계학의의（P＜0．05）。결론 Meta분석표명、재60세지전환자，제전성공여부여예후유밀절관계，이60세이상인군，제전시부성공여예후관계불대목전치료방전최유효、이차부작용최소적약물잉추천을알전부동。
Objective To compare the recent years,chronic atrial fibrillation,quinidine,amiodarone,moricizine,sotalol efficacy.Methods Chinese CNKI database to retrieve documents,included four drugs atrial fibrillation randomized controlled trials,using Revman5 .0 Meta-analysis software.Results quinidine,amiodarone better efficacy.There are more efficient than sotalol and moricizine,the difference was statistically significant (P<0.05).Conclusions Meta analysis showed that 60-year-old patient before defibrillation and prognosis of the success,and people over the age of 60,whether defibrillation suc-cess and prognosis is not currently the most effective treatment of atrial fibrillation,and minimal side effects of drugs still recommend amiodarone.
